{"id":"W3212274217","doi":"10.1136/jitc-2021-sitc2021.374","title":"374 A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Sanofi","keywords":"Pembrolizumab; Aflibercept; Medicine; Oncology; Internal medicine; Cancer; Bevacizumab; Immunotherapy; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008001628,0.0009354826,0.001046233,0.0002901141,0.0003939339,0.0007303398,0.0005610732,0.0008701373,0.005015036],"category_scores_gemma":[0.0003875409,0.0004314912,0.001075358,0.0002516058,0.0005964288,0.0005185911,0.0002333458,0.002447977,0.0009279061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00128684,"about_ca_system_score_gemma":0.001831591,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001869465,"about_ca_topic_score_gemma":0.004911193,"domain_scores_codex":[0.9997701,0.00008810863,0.00001386193,0.00003877107,0.0000236154,0.00006563395],"domain_scores_gemma":[0.9997358,0.00003090103,0.00003107925,0.00001211471,0.00001756108,0.0001725277],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7646522,0.05324489,0.009236126,0.0008807236,0.001344179,0.0003744193,0.0003030828,0.002463848,0.05589086,0.000460154,0.008600445,0.1025491],"study_design_scores_gemma":[0.6381229,0.337227,0.01380656,0.00003797859,0.0004534923,0.0002328822,0.00007631068,0.001105542,0.003410978,0.0002385449,0.005263592,0.00002423751],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877089,0.002187852,0.0003332791,0.001048011,0.0002486979,0.003348371,0.001279573,0.00006079662,0.003784544],"genre_scores_gemma":[0.988709,0.00155013,0.001185741,0.001247017,0.0002084312,0.001964445,0.002226315,0.00001507977,0.002893908],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005015036,"threshold_uncertainty_score":0.01677698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01062840677381271,"score_gpt":0.2660235208790911,"score_spread":0.2553951141052784,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}